
Results confirm safety and durability of haemophilia drug
Results from a Phase III trial have confirmed the durability and safety of a one-time infusion to treat adults living with moderate to severe haemophilia B. Etranacogene dezaparvovec, developed by global biopharma company CSL, was studied in a Phase III open-label, single-dose, single-arm trial, with 54 male participants… Read More











